Literature DB >> 12588535

The cytokine network in sarcoidosis and its clinical relevance.

M W Ziegenhagen1, J Müller-Quernheim.   

Abstract

In recent years, analysis of the cytokine network has substantially improved our knowledge of the immunopathogenesis of sarcoidosis. There is increasing evidence from clinical immunology that analysis of the cytokine network may be helpful for clinicians to assess the extent and activity of sarcoid inflammation. Genetic polymorphisms may contribute to interindividual differences in the regulation of cytokine release. Thus, disease phenotype-associated haplotypes should exist and their analysis might disclose risk profiles of individual patients. Furthermore, serological assessment of cytokines or soluble cytokine receptors may become suitable parameters in clinical practice to detect an ongoing inflammation in chronic sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588535     DOI: 10.1046/j.1365-2796.2003.01074.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  40 in total

1.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation.

Authors:  Thang Nguyen; Xikui K Liu; Yongliang Zhang; Chen Dong
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 3.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

4.  Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status.

Authors:  M A Spruit; M J Thomeer; R Gosselink; T Troosters; A Kasran; A J T Debrock; M G Demedts; M Decramer
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

5.  Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.

Authors:  Li Li; Lori J Silveira; Nabeel Hamzeh; May Gillespie; Peggy M Mroz; Annyce S Mayer; Tasha E Fingerlin; Lisa A Maier
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

6.  Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease.

Authors:  Karen C Patterson; Beverly S Franek; Joachim Müller-Quernheim; Anne I Sperling; Nadera J Sweiss; Timothy B Niewold
Journal:  Cytokine       Date:  2013-02-04       Impact factor: 3.861

7.  [Genetic risk profile of sarcoidosis].

Authors:  A Fischer; G Zissel; A Nebel; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

8.  The six-minute walk test in patients with pulmonary sarcoidosis.

Authors:  Esam H Alhamad
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

9.  Dramatic response to infliximab in refractory neurosarcoidosis.

Authors:  Sreekanth Chintamaneni; Aarat M Patel; Samuel B Pegram; Hirenkumar Patel; Heidi Roppelt
Journal:  Ann Indian Acad Neurol       Date:  2010-07       Impact factor: 1.383

10.  Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis.

Authors:  S K Metyas; R M Tadros; D G Arkfeld
Journal:  Rheumatol Int       Date:  2008-09-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.